Abstract. Chronic hepatitis B virus (CHB) infection is a major cause of cirrhosis and hepatocellular carcinoma. Nucleoside analogs (NAs) are popularly used to treat chronic hepatitis B virus (HBV) infections; however, the anti-HBV effect is attenuated by drug-resistant viral mutations selected during long-term antiviral therapy. The timely analysis of drugresistance mutations is essential in order to adjust treatment regimes. In this study, a T1699C substitution was introduced into the x gene of pHBV1.3 to generate an additional XhoI site, termed pHBV1.3-XhoI, which is a nonsense mutation and does not influence protein expression, HBV replication ability, or NA susceptibility. Based on co-transfection with weak or nonreplicative HBV plasmids and pHBV1.3-XhoI or pHBV1.3 and -XhoI-P-null plasmids into hepatocellular carcinoma cells, PCR was used to amplify 1176-bp segments of T/C1699 using the isolated HBV encapsulated DNA as a template, modified by XhoI digestion and subjected to agarose gel electrophoresis. Different bands composed of different virions were used to distinguish the replication capacities of the plasmids. Our results demonstrated no significant effects when different virions co-existed. A novel resistance test method was developed by co-transfection with pHBV1.3-XhoI and -rtL180M/M204V and treatment with various NA concentrations. Different bands composed of pHBV1.3-XhoI or -rtL180M/M204V were used to distinguish NA susceptibility. The bands composed of pHBV1.3 were more sharply reduced by lamivudine (LMV) than -rtL180M/M204V.
Introduction
Hepatitis B virus (HBV) is a significant human pathogen that causes serious health problems (1) and chronic HBV (CHB) infections affect more than 350 million individuals worldwide (2) , leading to the development of cirrhosis and hepatocellular carcinoma (3) . HBV is a hepadnavirus and replicates through reverse transcription of an RNA intermediate.
Until now, several nucleos(t)ide analogues (NAs), including lamivudine (LMV), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (LdT) and tenofovir (TDF), have been approved for the treatment of CHB and are powerful inhibitors of HBV replication (4, 5) . In vivo and in vitro, NAs mimic physiological nucleosides in terms of uptake and metabolism and are incorporated into newly synthesized DNA chains (6) , leading to synthesis inhibition through termination of DNA replication (7, 8) .
In CHB patients, HBV exists in the form of quasispecies due to the error-prone HBV reverse transcriptase (RT), which is responsible for the rich variety of drug-resistant mutants (9, 10) . HBV RT is subdivided into 7 domains (G, F and A-E), in which nearly all resistance mutations are located. NA-resistant mutations inhibit the anti-HBV effects of NAs and induce virological advancement and hepatopathological progression (5) . A number of mutations have been reported to account for drug resistance. Mutations of rtM204I or rtM204V in the YMDD motif within the RT domain of the HBV polymerase lead to LMV resistance (LMVr) and LdT resistance (LdTr) (11, 12) and they are usually accompanied by compensatory mutations of rtL180M and/or rtV173L that restore HBV replication capacity (13) . ETV resistance (ETVr) has also been observed in patients with LMVr (14) . Under the background of rtM204I/V, a combination of mutations in the B, C or D domains of RT may result in ETVr (15, 16) . The substitution mutations rtA181V/T or rtN236T can reduce the anti-HBV effects of ADV, while none have been reported to induce TDF resistance, apart from rtV214A, rtQ215S and rtA194T, although they require further confirmation (5, 17, 18) . Usually, when LMVr occurs, ADV remains effective (19, 20) . Due to a higher genetic barrier to HBV resistance than LMV and ADV, ETV and TDF are high potency drugs for the treatment of CHB patients, even those with LMVr and ADVr (21) .
Due to the broad spectrum of therapeutic options for anti-HBV therapy, HBV replication can be effectively inhibited in the absence of drug-resistance. Therefore, it is crucial to identify mutations through drug-resistant phenotype analysis and adjust treatments accordingly. In this study, an additional restriction site (XhoI) was introduced into pHBV1. 3 pHBV1.3-XhoI, which was distinguished from mutants without the XhoI site via PCR amplification and XhoI digestion after co-transfection. The T1699C substitution had no effect on the HBV replication level, antigenic protein production and secretion, or drug-sensitivity. Hence, pHBV1.3-XhoI can completely replace pHBV1.3 for drug-resistance research. Different virions were shown to co-exist in a single cell, which was achieved by co-transfection to closely resemble actual quasispecies.
The present study provides simple, practicable and adjustable methods for mimicing quasispecies for the identification of progeny viruses. Based on these methods, we addressed the co-existence of mutant (MT) and wild-type (WT) virions in individual cells and analyzed resistant MT phenotypes using novel methods. In the future, we aim to put this method into practice to discover resistance-related mutations and clarify whether the mutations affect NA susceptibility in vitro and in vivo.
Materials and methods
Plasmid constructs. pHBV1.3-MTs ( Fig. 1A ) with C669A/ A741G/T1699C/T2310C substitutions were introduced into the HBV genome by PCR-based mutagenesis using the primer pairs carrying specific mutations (Table I ) and pHBV1.3 (pBluescript KS + backbone) as the template, a replication-competent plasmid with 1.3-fold over-length genotype A genome (GenBank accession no. U95551, ayw) (22, 23) . The plasmids (pHBV1.3-rtM204V/I) were constructed in our previous study (24) .
NAs. Five types of NAs were used in this study, including LMV (3TC; GlaxoSmithKline, Middlesex, UK), ADV (Gilead Sciences, Middlesex, UK), ETV (Bristol-Myers Squibb Co., New Brunswick, NJ, USA), LdT (Novartis Pharmaceuticals Canada, Inc., Dorval, QC, Canada), and TDF (Gilead Sciences), which are all commercial pills that were ground, dissolved in appropriate solutions as per the manufacturers' instructions, and filtrated with 0.22-µm filters (Millipore Carrigtwohill, County Cork, Ireland). Based on the molecular weights and masses of each drug, the concentrations of the stock solutions were estimated and diluted to the required concentrations. The drugs were added to the assay medium at the indicated concentrations.
Cell culture and transfection. Huh7 cells, a hepatocellular carcinoma cell line, were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) at 37˚C in a 5% CO 2 atmosphere supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA), 2 mM/l of glutamine, 100 IU/ml of penicillin, and 100 IU/ml of streptomycin (25) . Huh7 cells were seeded in 6-well plates and transfected with 2 µg of plasmids per well using Lipofectamine 2000 (Invitrogen) with or without the indicated concentration of NAs (4). For transfection assays, HBV-bearing plasmids were co-transfected with a SEAP expression vector into Huh7 cells, the relative efficiency of transfections was assessed by measuring SEAP activity in the culture medium using a chemiluminescent detection method (26) .
Enzyme-linked immunosorbent assay (ELISA).
Huh7 cells were transfected with the indicated HBV-bearing plasmids, hepatitis B surface antigen (HBsAg), and hepatitis B e antigen (HBeAg) in the supernatant at 72 h post-transfection and were detected using the appropriate diagnostic kits (Shanghai Kehua Bio-Engineering Co., Ltd., Shanghai, China) according to the manufacturer's instructions.
Quantitative real-time PCR (qRT-PCR).
DNase I (Roche Diagnostics GmbH, Mannheim, Germany) was added to the cell lysis solution at 37˚C for 30 min to digest plasmid DNA. Total HBV DNA replicative intermediates were purified from Huh7 cell lysates 96 h post-transfection and used as templates for qRT-PCR, which was conducted using SYBRGreen I nucleic acid stain (Roche Diagnostics GmbH) on a LightCycler real-time thermal cycler (Applied Biosystems, Foster City, CA, USA) according to the manufacturers' instructions. Primers HBV-RC-F and HBV-RC-R (Table I) hybridized to the HBV surface gene were designed to quantify HBV-DNA relaxed circular (RC) genomes (100 bp fragments) by qRT-PCR relative to an external plasmid DNA standard.
Analysis of HBV DNA from intracellular core particles by
Southern blot analysis. Replication competent HBV WT and MT plasmids were transfected into Huh7 cells. HBV DNA replicative intermediates from intracellular core particles were extracted and diluted in 40 µl Milli-Q water, 20 µl of which were subjected to agarose gel electrophoresis, followed by denaturation and Southern blot analysis with 32 P-labeled full-length HBV probes according to previously published protocols (24) . Hybridization signals were visualized and analyzed by a phospho-imager (Cyclone ® Plus Storage Phosphor System; Parkard Instrument Company, Inc., Meriden, CT, USA). Data of densitometry analyses were quantified using OptiQuant software (PerkinElmer, Waltham, MA, USA).
Results

HBV plasmid construction.
A T1699C substitution in the x gene, T2310C in ATG of the P open reading frame, C669A (rtL180M) and A741G (rtM204V) were ligated into pHBV1.3 to obtain pHBV1.3-XhoI, -XhoI-P-null, and -rtL180M/ M204V, respectively (Fig. 1A) . Construction was carried out by fusion-PCR using primers carrying specific mutations and pHBV1.3 as the template. All of the molecular constructs were prepared using standard molecular biology techniques and their sequences were confirmed by restriction analysis and sequencing. The pHBV1.3 plasmid was digested with XhoI into 4782-and 1907-bp segments, while -XhoI and -XhoI-Pnull were cut into 4782-, 1568-and 339-bp segments (Fig. 2B) .
Replication and protein expression of WT and MT plasmids.
The plasmids, pHBV1.3, -XhoI, -XhoI-P-null, -rtM204V/I, and -rtL180M/M204V, were transfected into the Huh7 cells. HBsAg and HBeAg in the culture medium were subjected to ELISA. Replicative intermediates of HBV from intracellular core particles were extracted from the Huh7 cells and detected by Southern hybridization in a standard manner. A segment (1176 bp) from 1023 to 2199 bp was PCR-amplified using the above extracted DNA as the template and P-XhoI-F1 and P-XhoI-R4 as primers with or without XhoI digestion. Judging by the result of SEAP activity in the culture medium, the transfection efficiencies of the HBV-bearing plasmids were comparative (data not shown). pHBV1.3-XhoI and -rtL180M/ M204V had similar HBV replication levels as the WT plasmid, while -rtM204V/I had moderately depressed HBV replication, and WT-XhoI-P-null terminated HBV replication ( Fig. 2A,  upper panel) . All MT and WT plasmids expressed comparative HBs/eAg levels (Fig. 2E) . The results from PCR and digestion agreed with those from Southern blot analysis, which showed that only the PCR products from WT-XhoI could be digested into 2 smaller segments of 673 and 503 bp.
Two different HBV virions co-exist in individual Huh7 cells, but do not influence one another.
In order to examine the interplay between different HBV virions co-existing in individual Huh7 cells, HBV replication-competent plasmids were co-transfected into Huh7 cells and their replication capacities were detected by PCR and XhoI digestion. The pHBV1.3-rtA194T plasmid had a lower replication capacity and was not enhanced by pHBV1.3-XhoI and vice versa (Fig. 3C) .
Furthermore, the non-replicative pHBV1.3-XhoI-P-null plasmid, in which the initiator polymerase codon was mutated, was co-transfected with pHBV1.3 into the Huh7 cells (Fig. 3D) .
No specific dissected bands were obtained from the pHBV1.3-XhoI-P-null plasmid, indicating no replication rescue of pHBV1.3. These results were the precondition of our novel method constructed to analyze drug-resistant HBV phenotypes.
Southern blot analysis and real-time PCR to analyze drugresistant phenotypes of WT and MT HBV.
The HBV plasmids, pHBV1.3, -XhoI and -rtL180M/M204V, were transfected into the Huh7 cells and treated with different concentrations of NAs. The intracellular encapsulated HBV genomes were extracted and subjected to Southern blot analysis (Fig. 3) and real-time PCR (Fig. 4) targeted to HBV core-associated DNA and RC DNA, respectively. The anti-HBV effect of NAs and susceptibility variation between the WT and MT plasmids were estimated. WT and WT (XhoI) were sensitive to LMV (Fig. 3A) , LdT (Fig. 3B) , ADV (Fig. 3C) , ETV (Fig. 3D) and TDF (Fig. 3E) . However, rtL180M/M204V led to reduced susceptibility to LMV and LdT and attenuated the amplitude of the former more so than that of the later, but maintained similar sensitivities to ADV, ETV and TDF in the WT plasmid. The same conclusion was also drawn by real-time PCR analysis (Fig. 4) .
Novel method for the analysis of drug-resistant HBV phenotypes.
In order to eliminate the diversity resulting from transfection efficiencies and to simulate the quasispecies in patients, we co-transfected cells with pHBV1.3-XhoI and -rtL180M/M204V followed by treatment with various NA concentrations. The intracellular intracellular encapsulated HBV genomes viral genomes composed of pHBV1.3-XhoI and -rtL180M/M204V were extracted and distinguished by PCR and XhoI digestion. Only the products from the former could be cut into 2 sections by XhoI. Hence, the susceptibility difference to a given drug could be demonstrated by the change in specific band segments through agarose electrophoresis. ADV, ETV and TDF significantly inhibited all 3 segments ( Fig. 5A and C) , while LMV and LdT only inhibited the 503-and 673-bp segments and the 1176-bp segment composing rtL180M/M204V was suppressed more slowly than the 503-and 673-bp segments composing -XhoI. These results demonstrated that rtL180M/M204V was resistant to LMV and LdTl, and are in accordance with the results shown in Fig. 4 and those in previous reports. This novel method was successfully established for the analysis of drugresistant HBV phenotypes.
Discussion
As reported previously, due to the absence of HBV-RT proofreading capacity and its high replication rate, HBV exists as a quasispecies composed of a number of mutants that possess different fitness levels in certain environments. Due to the advantage of competitive replication, mutants with higher fitness levels may predominate in the total population and may differ in changing environments, such as the immune state of patients and treatment with interferon or NAs. As shown in previous studies, non-replicate HBV-RT mutations can be rescued by eukaryotic expression plasmids of HBV polymerase (27, 28) . In HBV quasispecies, it is unclear whether mutants with low replication capacity may be restored by a polymerase produced by mutants with normal replication capacities. In this study, we did not find this restoring phenomenon when viruses with various replication capacities co-existed. HBV-RT mutants with resistance to NAs are selected during long-term antiviral therapy; hence, these mutations will lead to virological breakthrough and therapeutic failure. Much research has been focused on drug-resistant mutations of HBV. The discovery of mutations for the analysis of novel resistance phenotypes is crucial and necessary for guiding the future development of antiviral medications.
The traditional detection method involves isolating HBV sequences from CHB patients and analyzing them for virological breakthrough to find drug-resistant mutations, which are then introduced into HBV replicon plasmids and transfected into Huh7/HepG2 cells in parallel with WT HBV and adding different NA concentrations to the culture medium. Susceptibilities to given drugs are then evaluated by Southern blot analysis or real-time PCR. Mutations that reduce susceptibility to a given drug are designated as resistance mutations. The novel method established in this study allowed for the more manageable and more rapid analysis of resistance phenotypes using regular PCR and restriction enzyme digestion. Certainly, PCR-digestion-based assay to distinguish HBV replication differences and susceptibility changes is not as convincing as 32 P-labeled Southern blot analysis. Only 20 cycles of PCR were run to minimize the deviation resulting from PCR amplification. As shown in Fig. 2A-D , PCR-digestion-based assay was successful in distinguishing the replication capacity and susceptibility differences of mutants and WT HBV to a given drug, which is in line with the Southern blot analysis results. Furthermore, 32 P-labeled Southern blot analysis, which is harmful to the environment and laboratory technicians, was avoided. Importantly, our co-transfection system allowed for a similar transfection efficiency of different plasmids and the co-existence of different virions in individual hepatocellular carcinoma cells to closely mimic actual quasispecies. Therefore, the replication capacity of WT (XhoI) and MT HBV can be successfully distinguished using greyscale analysis. In the future, we aim to refine this co-transfection system to achieve better standardization in vitro and aim to apply this method in vivo using a mouse model by hydrodynamic injection of an engineered, replication-competent HBV plasmid DNA into the tail veins of C57BL/6 mice.
